DK1007638T3 - KCNQ-kaliumkanaler og fremgangsmåde til modulering deraf - Google Patents

KCNQ-kaliumkanaler og fremgangsmåde til modulering deraf

Info

Publication number
DK1007638T3
DK1007638T3 DK98932877T DK98932877T DK1007638T3 DK 1007638 T3 DK1007638 T3 DK 1007638T3 DK 98932877 T DK98932877 T DK 98932877T DK 98932877 T DK98932877 T DK 98932877T DK 1007638 T3 DK1007638 T3 DK 1007638T3
Authority
DK
Denmark
Prior art keywords
kcnq2
proteins
kcnq3
potassium channels
disease
Prior art date
Application number
DK98932877T
Other languages
Danish (da)
English (en)
Inventor
Steven Dworetzky
Valentin K Gribkoff
Wen-Pin Yang
Michael A Blanar
Paul C Levesque
Michael G Neubauer
Wayne A Little
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21998937&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1007638(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Application granted granted Critical
Publication of DK1007638T3 publication Critical patent/DK1007638T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Steroid Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
DK98932877T 1997-08-12 1998-06-26 KCNQ-kaliumkanaler og fremgangsmåde til modulering deraf DK1007638T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5559997P 1997-08-12 1997-08-12
PCT/US1998/013276 WO1999007832A1 (en) 1997-08-12 1998-06-26 Kcnq potassium channels and methods of modulating same

Publications (1)

Publication Number Publication Date
DK1007638T3 true DK1007638T3 (da) 2007-05-21

Family

ID=21998937

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98932877T DK1007638T3 (da) 1997-08-12 1998-06-26 KCNQ-kaliumkanaler og fremgangsmåde til modulering deraf

Country Status (10)

Country Link
US (4) US6403360B1 (de)
EP (1) EP1007638B1 (de)
JP (1) JP2001512673A (de)
AT (1) ATE356200T1 (de)
AU (1) AU731087B2 (de)
CA (1) CA2300985A1 (de)
DE (1) DE69837267T2 (de)
DK (1) DK1007638T3 (de)
ES (1) ES2281129T3 (de)
WO (1) WO1999007832A1 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2281129T3 (es) * 1997-08-12 2007-09-16 Bristol-Myers Squibb Company Canales de potasio kcnq y procedimientos para su modulacion.
US6413719B1 (en) 1997-10-24 2002-07-02 University Of Utah Research Foundation KCNQ2 and KCNQ3-potassium channel genes which are mutated in benign familial neonatal convulsions (BFNC) and other epilepsies
JP2002543768A (ja) * 1999-04-14 2002-12-24 メルク エンド カムパニー インコーポレーテッド 新規ヒト電位依存性カリウムチャンネル
US6649371B1 (en) 1999-06-11 2003-11-18 Neurosearch A/S Potassium channel KCNQ5 and sequences encoding the same
JP4833467B2 (ja) * 1999-06-11 2011-12-07 ニューロサーチ、アクティーゼルスカブ 新規カリウムチャネル及び同カリウムチャネルをコードする遺伝子
US6472165B1 (en) 1999-08-03 2002-10-29 Arzneimittelwerk Dresden Gmbh Modulatory binding site in potassium channels for screening and finding new active ingredients
JP2003506388A (ja) 1999-08-04 2003-02-18 アイカゲン インコーポレイテッド 疼痛および不安症を処置または予防するための方法
DE10013732A1 (de) * 2000-03-21 2001-09-27 Aventis Pharma Gmbh Das Kaliumkanalprotein KCNQ5, ein neuer Angriffspunkt bei Erkrankungen des zentralen Nervensystems und des Herz-Kreislauf-Systems
US6617131B2 (en) 2000-03-21 2003-09-09 Aventis Pharma Deutschland Gmbh Nucleic acid molecule encoding the potassium channel protein, KCNQ5
US7049137B2 (en) 2000-03-21 2006-05-23 Icagen, Inc. KCNQ5, a novel potassium channel
US6767736B2 (en) * 2000-04-03 2004-07-27 Lexicon Genetics Incorporated Human ion channel protein and polynucleotides encoding the same
US6893858B2 (en) * 2000-05-26 2005-05-17 Bristol-Myers Squibb Company Human kcnq5 potassium channel, methods and compositions thereof
US6348486B1 (en) * 2000-10-17 2002-02-19 American Home Products Corporation Methods for modulating bladder function
WO2002072088A2 (en) * 2001-02-20 2002-09-19 Bristol-Myers Squibb Company Modulators of kcnq potassium channels and use thereof in treating migraine and mechanistically related diseases
RU2607033C2 (ru) * 2010-09-28 2017-01-10 Ноно Инк. Пептиды nd2 и способы лечения неврологического заболевания
FR3029113A1 (fr) * 2014-12-02 2016-06-03 Univ Paris-Sud Composes pour le traitement des maladies mitochondriales
US20230124616A1 (en) * 2020-03-06 2023-04-20 Ionis Pharmaceuticals, Inc. Compounds and methods for modulating kcnq2

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09191882A (ja) * 1996-01-16 1997-07-29 Japan Tobacco Inc ヒト新規ｋ＋チャネル蛋白質をコードするｄｎａおよびその断片
ES2281129T3 (es) * 1997-08-12 2007-09-16 Bristol-Myers Squibb Company Canales de potasio kcnq y procedimientos para su modulacion.
US6413719B1 (en) * 1997-10-24 2002-07-02 University Of Utah Research Foundation KCNQ2 and KCNQ3-potassium channel genes which are mutated in benign familial neonatal convulsions (BFNC) and other epilepsies

Also Published As

Publication number Publication date
CA2300985A1 (en) 1999-02-18
ES2281129T3 (es) 2007-09-16
WO1999007832A1 (en) 1999-02-18
US7262289B2 (en) 2007-08-28
US6403360B1 (en) 2002-06-11
DE69837267T2 (de) 2007-10-31
US20030044912A1 (en) 2003-03-06
JP2001512673A (ja) 2001-08-28
US7041496B2 (en) 2006-05-09
EP1007638B1 (de) 2007-03-07
AU731087B2 (en) 2001-03-22
ATE356200T1 (de) 2007-03-15
US7482431B2 (en) 2009-01-27
US20070148692A1 (en) 2007-06-28
EP1007638A1 (de) 2000-06-14
US20020168724A1 (en) 2002-11-14
DE69837267D1 (de) 2007-04-19
AU8266598A (en) 1999-03-01
EP1007638A4 (de) 2004-12-29

Similar Documents

Publication Publication Date Title
DK1007638T3 (da) KCNQ-kaliumkanaler og fremgangsmåde til modulering deraf
FR18C1021I2 (fr) Methode de regulation de l'activite d'une molecule immunologiquement fonctionnelle
DK0996463T3 (da) Katalytiske monoklonale antistoffer med proteaseaktivitet til selektiv lysis af proteinbestanddelen af plaques og aggregater beslægtet med patologiske tilstande
MXPA02001911A (es) Anticuerpos ctla-4 humanos y sus usos.
DE69637256D1 (de) Synthese von Methoxynukleoside und enzymatische Nukleisäure Moleküle
NO970042D0 (no) 2-£(Dihydro)pyrazolyl-3'-oksymetylen|-anilider, fremgangsmåte til fremstilling og anvendelse derav
CY1111542T1 (el) Αντισωματα εξουδετερωσης του rsv υπερυψηλης συγγενειας
IL152663A0 (en) Novel multicyclic compounds and the use thereof
DE69626539D1 (de) topische Verwendung von Vitamin D zur Behandlung von Augenerkrankungen
WO2004058704A3 (en) Quinazolinones as potassium channel modulators
WO2002076494A3 (en) USE OF CYTOKINES OF THE TGF-β SUPERFAMILY FOR THE TREATMENT AND DIAGNOSIS OF SKIN RELATED DISORDERS
DE59910902D1 (de) Verwendung von Chitosanmikropaseln zur Herstellung dekorativer kosmetischer Zubereitungen
ATE299179T1 (de) Menschliche suppressor trna oligonukleotide und verfahren für deren verwendung
ATE391779T1 (de) Aus dem menschlichen gehirn stammender kcnq2 kaliumkanal
WO2001031008A3 (en) Human and rat fgf-20 genes and gene expression products
EA200001246A1 (ru) Карбамиды и карбаматы n-гетероциклических карбоновых кислот и изостер карбоновых кислот
ATE291621T1 (de) Nukleinsaeuren und proteine der katze fc-epsilon rezeptor alpha-kette und deren verwendungen
ATE550345T1 (de) Sfrp, mit sfrp-interagierende peptidmotive sowie verwendungsverfahren
BR9704615A (pt) formononetina de metal alcalino e processo de estimulação micorrizal
EP1331265A3 (de) Durch Zelldichte stimulierte Protein-Tyrosin-Phosphatasen
DE69812861D1 (de) Walzwerk zur herstellung von axialsymmetrischen teilen
WO2005002573A3 (en) Methods for using modulators of proline-rich tyrosine kinase 2
WO2003040320A3 (en) Antisense modulation of human collapsin response mediator protein 2 expression
ATE391915T1 (de) Verwendung des proteins grf-1 zur auswahl von molekülen
DE59808160D1 (de) Zusammensetzung zur behandlung von gegerbtem leder, sowie ihre herstellung